Search Results
Your search for ,ASh matches 1590 pages
Showing 1 - 50Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy, or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989, given as monotherapy or in combination with...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
First Results of Phase III OLYMPIA-3: Odronextamab Plus CHOP in Untreated DLBCL
The bispecific antibody odronextamab plus standard CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy yielded robust and durable responses in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL), based on the first results of the phase III OLYMPIA-3 study...
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Treatment with the novel CD123-targeting antibody-drug conjugate pivekimab sunirine led to a high rate of complete and durable responses in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially among patients being treated in the front-line setting. The antibody-drug...
ASH Guidelines on Management of Newly Diagnosed and Relapsed/Refractory ALL in AYA Patients
The American Society of Hematology (ASH) released guidelines on front-line management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population. Both guidelines, grounded in evidence-based practice,...
ASH Publishes Clinical Guidelines on AL Amyloidosis Diagnosis
The American Society of Hematology (ASH) has released clinical practice guidelines on the diagnosis of light chain (AL) amyloidosis, which were published in Blood Advances. Additionally, the expert panel behind the guidelines also published a scoping review about the clinical features of systemic...
Early Findings From First Human Study of In Vivo CAR T in Myeloma
The first-in-human clinical trial of an in vivo CAR T-cell therapy for multiple myeloma has shown encouraging clinical outcomes at an early time point, with a safety profile and ease of administration that indicates the off-the-shelf KLN-1010 could be easily deployable, researchers from Australia...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib...
Epcoritamab Plus R2 in Follicular Lymphoma: A Potential New Treatment Standard
In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of disease progression or death by almost 80% over R2 alone, based on the primary analysis of the phase...
GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting
As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive...
Highlights From the 2025 ASH Annual Meeting & Exposition
At this year’s American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, we had the opportunity to navigate both manned and unmanned traffic, contend with temperamental weather, and count our steps as we took in the most consequential developments in hematologic oncology....
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of...
A Paradigm Shift in Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma
A higher absolute lymphocyte count (ALC) after receipt of chimeric antigen receptor (CAR) T-cell therapy may be associated with improved progression-free and/or overall survival in patients with non-Hodgkin lymphoma, according to findings from the 2025 American Society of Hematology (ASH) Annual...
Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange
Mikkael Sekeres, MD, MS, Chief, Division of Hematology and Professor of Medicine at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presents findings from a new study that connects exposure to the herbicide Agent Orange to earlier and more severe...
Nitin Jain, MD, on a Triplet Regimen for Richter Transformation
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews findings from a phase II trial of pirtobrutinib, venetoclax, and obinutuzumab for patients with Richter transformation (Abstract 89).
Data Published on Incidence of Immune Checkpoint Inhibitor–Associated ITP
Researchers have published valuable information about a rare but serious complication of cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course and underscoring the importance of early diagnosis and treatment. The findings were published by Leaf et ...
CD123-Targeting ADC Shows Activity in AML and BPDCN
Researchers presented new data from two ongoing studies of pivekimab sunirine, an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 2025 American Society of Hematology (ASH) Annual Meeting & Exposition. In a phase Ib/II trial led by Naval Daver, MD,...
Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab
Andrew Portuguese, MD, of Fred Hutchinson Cancer Center, discusses findings from a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium looking at the real-world safety and efficacy of the BCMA-CD3 bispecific antibody elranatamab (Abstract 136).
Amer Zeidan, MBBS, on TP53-Mutated Higher-Risk MDS: Bexmarilimab Plus Azacitidine
Amer Zeidan, MBBS, of Yale School of Medicine, shares results from the phase I/II BEXMAB study, which examined the safety, tolerability and preliminary efficacy of bexmarilimab—a novel macrophage checkpoint inhibitor targeting Clever-1—in combination with the standard of care, azacitidine, in...
Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response
Amer Zeidan, MBBS, of Yale School of Medicine, discusses findings from an analysis of the IMerge trial, which explored the possible association between imetelstat-related cytopenias and hemoglobin increase—a measure linked to red blood cell transfusion independence achievement—in patients with...
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
The addition of the investigational monoclonal antibody ianalumab to eltrombopag extended the time to treatment failure in patients with primary immune thrombocytopenia (ITP) after prior treatment with corticosteroids, according to findings from the phase III VAYHIT2 trial presented at the 2025...
Follicular Lymphoma: Durable Remissions and Sustained Safety With Third-Line Lisocabtagene Maraleucel
Patients with relapsed or refractory follicular lymphoma treated in the third-line setting with a single infusion of the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel continued to show responses after 3 years, according to long-term follow-up results from the TRANSCEND FL...
CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker in angioimmunoblastic T-cell lymphoma (AITL), a rare subtype of non-Hodgkin lymphoma that is difficult to diagnose and treat. The results of their study were...
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for patients with lower-risk myelodysplastic syndromes (MDS). The researchers compared three abbreviated...
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
The noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to findings from a randomized...
Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
Initial results from the phase III GIMEMA ALL2820 trial demonstrated that a front-line, chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed a standard treatment strategy of imatinib plus...
Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma
Updated findings from the phase II iMMagine-1 study show that anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for relapsed or refractory multiple myeloma, continues to deliver high response rates with a reassuring safety profile. Researchers from The University of Texas ...
Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma
When epcoritamab was added to lenalidomide and rituximab, response rates were significantly higher and progression-free survival was prolonged for patients with follicular lymphoma treated in the second-line setting or beyond, according to findings from the phase III EPCORE FL-1 trial presented at...
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
The combination of azacitidine and venetoclax led to improved efficacy outcomes with fewer complications than standard intensive induction chemotherapy as upfront treatment for patients with acute myeloid leukemia (AML), according to trial findings presented at the 2025 American Society of...
Jennifer Woyach, MD, on Relapsed/Refractory CLL: Next-Generation BTK Inhibitor
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, reviews phase I data on rocbrutinib, a new selective next-generation inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and prior exposure to BTK and/or...
Jennifer Woyach, MD, on CLL/SLL: Pirtobrutinib vs Ibrutinib in Treatment-Naive and Relapsed/Refractory Disease
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results from the first head-to-head comparison of pirtobrutinib vs ibrutinib in treatment-naive patients and patients with covalent Bruton tyrosine kinase inhibitor–naive relapsed/refractory chronic lymphocytic ...
Brian Ball, MD, on Higher-Risk MDS: Bexmarilimab and Azacitidine
Brian Ball, MD, of City of Hope, presents updated results from the phase I/II BEXMAB study. They showed that the doublet had encouraging activity in patients with TP53-mutant, higher-risk MDS; translational data support the combination regimen’s potential for altering immune dysregulation in this...
Alexander Lesokhin, MD: Can Patients With Relapsed/Refractory Multiple Myeloma Successfully Pause or Discontinue Elranatamab?
Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses results of a retrospective analysis from the phase II MagnetisMM-3 trial. A post hoc analysis was conducted of the subgroup of patients enrolled in the study who had a prolonged treatment interruption or who permanently...
ASH Recognizes Leaders for Support of Patient Care and Research
The American Society of Hematology (ASH) will honor U.S. Senators Susan Collins (R-ME), Patty Murray (D-WA), Shelley Moore Capito (R-WV), and Tammy Baldwin (D-WI), as well as the patient groups Sick Cells, The Sickle Cell Disease Association of America (SCDAA), and The Sickle Cell Disease...
Rainer Storb, MD, Receives Distinguished Wallace H. Coulter Award at ASH Annual Congress
The American Society of Hematology (ASH) presented the Wallace H. Coulter Award for Lifetime Achievement in Hematology to Rainer Storb, MD, during the Society’s Annual Congress held in Orlando. Dr. Storb is Professor Emeritus, Clinical Research Division, at Fred Hutch in Seattle. First awarded in...
One in Three Families of Children With ALL Face Financial Hardship During Treatment
A new multicenter study reports that nearly one-third of families with children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) develop substantial financial hardships during the 2 years of treatment. These difficulties—defined as the inability to pay for housing, food, or utilities, ...
Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, on Ultra–High-Risk Multiple Myeloma: RADAR Trial in Newly Diagnosed Transplant-Eligible Patients
Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, of the University of Oxford, discusses initial results of the phase II/III UK-based RADAR trial. The study evaluated isatuximab, bortezomib, lenalidomide, dexamethasone, and cyclophosphamide induction, followed by single autologous stem cell transplant,...
Non–Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Two-year event-free survival rates were above 75% for children, adolescent, and young adult patients with B-cell acute lymphocytic leukemia (B-ALL) who had negative measurable residual disease (MRD) by next-generation sequencing prior to hematopoietic cell transplantation and who received a...
Cyclophosphamide-Based Strategy Enables Safe Transplant From Broadly Mismatched Donors
Clinicians have traditionally prioritized high-level human leukocyte antigen (HLA) matching to minimize graft-vs-host disease (GVHD) after hematopoietic cell transplantation (HCT). New data from the ACCESS study, sponsored by the National Marrow Donor Program, indicate that the use of...
